Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition

Link to article at PubMed

Cleve Clin J Med. 2021 Mar 1. doi: 10.3949/ccjm.87a.ccc060. Online ahead of print.


This review focuses on an alternative strategy utilizing small molecules to inhibit a key signal-transduction pathway, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. The JAK-STAT pathway mediates biologic activity for a large number of inflammatory cytokines and mediators.

PMID:32847819 | DOI:10.3949/ccjm.87a.ccc060

Leave a Reply

Your email address will not be published.